CJC-1295 with DAC is a long-acting growth hormone-releasing hormone (GHRH) analog designed for once- or twice-weekly injection, used to raise GH and IGF-1 levels over sustained periods.
What it does
CJC-1295 with DAC works the same way at the receptor level as its shorter-acting cousin: it binds to GHRH receptors (GHRHR) on pituitary somatotrophs — the cells that make and release growth hormone — triggering a cAMP/PKA signaling cascade that prompts GH secretion. What makes this version different is the DAC moiety (Drug Affinity Complex), a reactive chemical group that, after injection, covalently bonds to albumin, the most abundant protein in blood. That albumin attachment shields the peptide from rapid breakdown, extending its half-life from roughly 30 minutes to 6–8 days al. 2006.
The consequence of that extended half-life is continuous GHRH receptor stimulation rather than the brief, pulsatile stimulation your body naturally uses. Research by Ionescu and Frohman found that GH pulsatility is technically preserved — the pituitary still fires in pulses — but trough GH levels (the baseline between pulses) are elevated roughly 7.5-fold, creating a persistent low-level GH 'bleed' rather than sharp peaks followed by near-zero troughs M 2006. This is a meaningful physiological distinction: normal GH signaling is episodic, and chronically elevated troughs are associated with more GH-related side effects than pulsatile peaks of similar magnitude.
What the evidence shows
Sustained GH and IGF-1 elevation Two small human trials; no long-term controlled data
The foundational human trial showed that a single injection of CJC-1295 with DAC produced dose-dependent increases in GH and IGF-1 that lasted up to 6 days, with IGF-1 remaining elevated for 1–2 weeks in some participants al. 2006. A separate study confirmed that pulsatile GH secretion continues during this sustained stimulation, though baseline GH between pulses is substantially higher than normal M 2006. Both studies involved healthy adults in controlled settings; neither was designed to evaluate clinical outcomes like body composition, recovery, or longevity.
Convenience over nightly injection protocols Pharmacokinetic data from human trials; outcome comparisons with no-DAC formulation are absent
The DAC formulation's primary practical argument is dosing frequency: once or twice weekly versus nightly subcutaneous injections required with shorter-acting GHRH analogs. The half-life data supports this al. 2006, but no head-to-head trial has compared clinical outcomes — muscle mass, fat loss, recovery — between DAC and no-DAC protocols. The trade-off is a less physiologic GH profile M 2006, which most clinicians consider a real cost, not a minor footnote.
How it's used
In studies and self-reported protocols, doses range from 1 mg subcutaneously once weekly on the low end, to 2 mg once weekly as a moderate dose, to 2 mg twice weekly at the high end. Because the DAC moiety creates a sustained GH elevation regardless of injection timing, there is no established benefit to timing the injection relative to sleep or meals — unlike pulsatile GHRH analogs, where pre-sleep dosing mimics natural GH rhythms. The peptide is administered subcutaneously, typically into abdominal fat. Given the 6–8 day half-life, steady-state blood levels build over several weeks of weekly dosing.
Side effects and safety
Reported side effects track closely with GH excess in general. Mild effects include water retention, injection site reactions, and tingling at the extremities. Moderate effects include joint swelling, headache, and the persistent non-pulsatile GH elevation itself — which some consider an inherent hazard rather than a side effect. The chronically elevated GH trough raises concerns about insulin resistance, since GH antagonizes insulin signaling at the tissue level. Severe risks include potential stimulation of pre-existing occult tumors, given that GH and IGF-1 are growth-promoting hormones; this is why active malignancy and a history of tumor are listed as contraindications. Sleep apnea may worsen with GH elevation. Long-term safety data in humans simply does not exist — both cited studies are short-duration pharmacokinetic trials, not safety studies.
Bottom line
CJC-1295 with DAC has solid short-term human pharmacokinetic data showing it does what it claims — raise GH and IGF-1 for days per injection. The cost is a less physiologic, continuously elevated GH profile that carries more side effect risk than pulsatile alternatives, and there are no long-term human safety or efficacy trials. It is a reasonable consideration only for someone who genuinely cannot manage more frequent injection protocols and who understands they are trading physiologic accuracy for convenience.